Transforming the Way Pruritus is Treated.
Cara Therapeutics is advancing life-changing therapies for people suffering from chronic pruritus. Our proven science and expert team are changing the way pruritus is treated across a spectrum of diseases.
More than just an itch.
Pruritus is defined as an unpleasant sensation that provokes the desire to scratch, but we know it’s much more than that. Chronic pruritus can be a devastating, disabling, and burdensome condition that significantly impairs quality of life. The millions of people who suffer from pruritus deserve relief.
Focus in Pruritus
Hemodialysis
Approved
About 200K patients undergoing hemodialysis (HD) suffer from a moderate to severe intractable itch. Cara has developed and launched the first and only product approved to help these patients.
Predialysis
Phase 3
There are over 300K patients with advanced CKD that suffer from moderate to severe pruritus and there are no approved therapies.
Atopic Dermatitis
Phase 3
Atopic Dermatitis (AD) is the most common chronic pruritic inflammatory dermatosis affecting up to 2-10% of adults worldwide. Moderate to severe chronic pruritus is one the defining features of AD.
Notalgia Paresthetica
Phase 2
Pruritus in Notalgia Paresthetica (NP) is a common, but under-recognized neuropathic itch typically in the upper back affecting ~650K patients. There are no approved therapies to treat pruritus from NP.